57th ASH Annual Meeting and Exposition (December 5-8, 2015): 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: B-cell Receptor Signaling and Resistance in Lymphoma

Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents Oral and Poster Abstracts
Oral

Hall E2, Level 2 (Orange County Convention Center)

Moderators:

Robert A Baiocchi, MD, PhD, The Ohio State University and Holbrook E Kohrt, MD, Ph.D., Stanford University School of Medicine

Disclosures:

No relevant conflicts of interest to declare.

2:45 PM

703

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Aneel Paulus, MD, MS¹, Sharoon Akhtar, MPhil²^*, Kelara Samuel³^*, Hassan Yousaf⁴^*, Davitte Cogen⁴^*, Jennifer Jiang⁴^*, Abhisek Swaika, MBBS⁵^*, Anne Novak, PhD⁶, Stephen M Ansell, M.D., Ph.D.⁷, Morie A Gertz, M.D.⁷, Robert A. Kyle, MD⁷, Thomas E. Witzig, MD⁷, George J Weiner, MD⁸, Peter Martin, MD⁹, Morton Coleman, MD¹⁰, Sikander Ailawadhi, MD¹¹, Joachim Gullbo, MD, PhD¹²^*, Stig Linder, Ph.D¹³^*, Geraldo Otero-Colon³^*, Vivek Roy, MD¹⁴, Kasyapa S. Chitta, PhD¹ and Asher Alban Chanan-Khan, MD¹¹

¹Cancer Biology, Mayo Clinic, Jacksonville, FL
²Department of Cancer Biology, Mayo Clinic, Jacksonville, FL
³Mayo Clinic, Jacksonville
⁴Mayo Clinic, Jacksonville, FL
⁵Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL
⁶Mayo Clinic, Rochester, MN
⁷Division of Hematology, Mayo Clinic, Rochester, MN
⁸University of Iowa, Iowa City, IA
⁹Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY
¹⁰Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York, NY
¹¹Division of Hematology & Oncology, Mayo Clinic, Jacksonville, FL
¹²Uppsala University, Uppsala, Sweden
¹³Karolinska, Stockholm, Sweden
¹⁴Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL

3:00 PM

704

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Marco Ruella, MD¹, Saad S Kenderian, MD¹, Olga Shestova, PhD¹^*, Joseph A. Fraietta, PhD¹^*, Sohail Qayyum, MD²^*, Qian Zhang, MD, PhD²^*, Marcela V. Maus, MD, PhD¹, Xiaobin Liu, PhD²^*, Selene Nunez-Cruz, PhD¹^*, Michael Klichinsky, PharmD¹^*, Omkar Uday Kawalekar, MS, BS¹, Michael C. Milone, MD, PhD¹^*, Simon F. Lacey, PhD, BSc¹^*, Anthony Mato, MD³^*, Stephen J. Schuster, MD⁴, Michael Kalos, PhD², Carl H. June, MD¹, Saar I Gill, MBBS, PhD¹ and Mariusz A. Wasik, MD⁵^*

¹Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
²Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
³Center for Chronic Lymphocytic Leukemia, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁴Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA
⁵Pathology and Laboratory Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

3:15 PM

705

HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma

Guang Yang, PhD¹, Sara Buhrlage, PhD²^*, Li Tan, PhD²^*, Xia Liu, MD¹^*, Jie Chen, PhD¹^*, Zachary Hunter, PhD¹^*, Lian Xu¹^*, Nicholas Tsakmaklis¹^*, Jiaji Chen¹^*, Christopher J Patterson, MFA¹^*, Jorge J Castillo, MD³, Wei Zhang, PhD⁴^*, Nathanael Gray, PhD²^* and Steven P Treon, MD, PhD¹

¹Bing Center for WM, Dana Farber Cancer Institute, Boston, MA
²Dept of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA
³Division of Hematologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁴College of Science and Mathematics, University of Massachusetts, Boston, MA

3:30 PM

706

A Novel Pan-PIM Kinase Inhibitor, SEL24-B489, Induces Apoptosis and Inhibits Proliferation of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation of Myc and NFkB Activity

Ewa Jablonska, PhD¹^*, Maciej Szydlowski, PhD¹^*, Emilia Bialopiotrowicz, PhD¹^*, Przemyslaw Kiliszek, MSc¹^*, Tomasz Sewastianik, MSc¹^*, Anna Polak, MSc¹^*, Krzysztof Warzocha, MD, PhD²^*, Wojciech Czardybon, PhD³^*, Michal Galezowski, PhD³^*, Renata Windak, PhD³^*, Aniela Golas, PhD³^*, Krzysztof Brzozka, PhD³^* and Przemyslaw Juszczynski, MD, PhD¹^*

¹Dept. of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
²Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
³Selvita S.A., Cracow, Poland

3:45 PM

707

Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma

Lan Pham, PhD¹, Liang Zhang, MD, PhD², Wenjing Tao, PhD²^*, Donglu Zhao, MD²^*, Hui Zhang²^*, Jingmeng Xie²^*, Jack Wang²^*, Krystle Nomie, PhD²^* and Michael Wang, MD^2,3

¹Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

4:00 PM

708

Synergistic Co-Targeting of BTK and BCL2 in Mantle Cell Lymphoma

Yangguang Li, PhD¹, Myriam N. Bouchlaka, BS, PhD², Kreg Grindle¹^*, Brad S Kahl, MD³, Shigeki Miyamoto⁴^*, David T Yang, MD⁵, Christian M. Capitini, MD⁶ and Lixin Rui, PhD⁷

¹Department of Medicine, Madison, WI
²Department of Pediatrics and Carbone Cancer Center, University of Madison, Wisconsin, Madison, WI
³Washington University, St.Louis, MO
⁴Department of Oncology, madison, WI
⁵Pathology and Laboratory Medicine, and Carbone Cancer Center, Madison, WI
⁶Department of Pediatrics, Madison, WI
⁷Department of Medicine and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI

See more of: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

625.O1.6 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: B-cell Receptor Signaling and Resistance in Lymphoma